4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
Moderna and Merck report success in Phase 3 melanoma trial for mRNA cancer vaccine
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 trial for melanoma, involving 1,137 patients. The trial compared the vaccine combined with Keytruda to Keytruda alone, conducted in a double-blind and placebo-controlled format.
Our neutral summary
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 trial for melanoma, involving 1,137 patients. The trial compared the vaccine combined with Keytruda to Keytruda alone, conducted in a double-blind and placebo-controlled format.
Read the full story at Ars Technica ↗
The reporting belongs to
Ars Technica;
we don't reproduce it.
You can compare how outlets framed this story below.